Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Autor: Jackson, GH, Davies, FE, Pawlyn, C, Cairns, DA, Striha, A, Collett, C, Hockaday, A, Jones, JR, Kishore, B, Garg, M, Williams, CD, Karunanithi, K, Lindsay, J, Jenner, MW, Cook, G, Russell, NH, Kaiser, MF, Drayson, MT, Owen, RG, Gregory, WM, Morgan, GJ, UK NCRI Haemato-oncology Clinical Studies Group

BACKGROUND: Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide maintenance therapy on ove

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::5ba626b460de311f4bf4538fcef58dba
https://eprints.whiterose.ac.uk/140642/1/1-s2.0-S1470204518306879-main.pdf

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1,905 trial patients

Autor: Shah, V, Sherborne, AL, Walker, BA, Johnson, DC, Boyle, EM, Ellis, S, Begum, DB, Proszek, PZ, Jones, JR, Pawlyn, C, Savola, S, Jenner, MW, Drayson, MT, Owen, RG, Houlston, RS, Cairns, DA, Gregory, WM, Cook, G, Davies, F, Jackson, GH, Morgan, GJ, Kaiser, MF

Robust establishment of survival in multiple myeloma (MM) and its relationship to recurrent genetic aberrations is required as outcomes are variable despite apparent similar staging. We assayed copy number alterations (CNA) and translocations in 1036

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::85ee3ae844525eae55a5c49d73e065df
https://eprints.whiterose.ac.uk/117302/16/leu2017179a.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.

Autor: Kaiser MF; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Hall A; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Walker K; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Sherborne A; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom., De Tute RM; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Newnham N; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Roberts S; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Ingleson E; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Bowles K; Department of Haematology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom., Garg M; Department of Haematology, Leicester Royal Infirmary, Leicester, United Kingdom., Lokare A; Department of Haematology, Birmingham Heartlands, Birmingham, United Kingdom., Messiou C; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.; Department of Haematology, The Royal Marsden Hospital, London, United Kingdom., Houlston RS; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom., Jackson G; Department of Haematology, Newcastle University, Newcastle, United Kingdom., Cook G; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.; Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Pratt G; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Owen RG; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, United Kingdom., Drayson MT; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Brown SR; Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom., Jenner MW; Department of Haematology, University Hospital Southampton, Southampton, United Kingdom.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Aug 10; Vol. 41 (23), pp. 3945-3955. Date of Electronic Publication: 2023 Jun 14.

Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.

Autor: Faustini SE; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Hall A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Brown S; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Roberts S; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Hill H; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Stamataki Z; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Jenner MW; Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK., Owen RG; The Leeds Teaching Hospitals NHS Trust, Leeds, UK., Pratt G; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Cook G; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.; The Leeds Teaching Hospitals NHS Trust, Leeds, UK., Richter A; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Drayson MT; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., Kaiser MF; The Royal Marsden Hospital NHS Foundation Trust, London, UK.; The Institute of Cancer Research, London, UK., Heaney JLJ; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Publikováno v: British journal of haematology [Br J Haematol] 2023 Jun; Vol. 201 (5), pp. 845-850. Date of Electronic Publication: 2023 Mar 09.